Summary

The 7 major systemic mastocytosis markets reached a value of US$ 256.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 455.5 Million by 2034, exhibiting a growth rate (CAGR) of 5.38% during 2024-2034.

The systemic mastocytosis market has been comprehensively analyzed in IMARC's new report titled "Systemic Mastocytosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Systemic mastocytosis refers to a rare disorder that is mainly characterized by the abnormal accumulation of mast cells in different body organs and tissues, including the skin, bone marrow, liver, spleen, gastrointestinal tract, etc. Some of the common disease symptoms are skin lesions or rash, itching, flushing, abdominal pain, diarrhea, nausea, vomiting, muscle and bone pain, fatigue, anaphylactic reactions, etc. Other symptoms include headache, palpitations, dizziness, low blood pressure, etc. Systemic mastocytosis can also lead to numerous complications, such as osteoporosis, anemia, and liver or spleen enlargement. The diagnosis is usually based on a combination of clinical evaluation, medical history, physical examination, and laboratory tests. Blood tests are performed to measure the levels of mast cell mediators, such as tryptase, and to look for genetic mutations associated with the disease. Additionally, a bone marrow biopsy is commonly performed to assess the number of mast cells in the bone marrow and to look for specific abnormalities indicative of systemic mastocytosis. In some cases, various imaging tests, such as CT or MRI scans, may be used to assess the extent of organ involvement.

The increasing cases of genetic mutations and the rising prevalence of several associated risk factors, such as exposure to certain chemicals and environmental toxins, viral infections, etc., are primarily driving the systemic mastocytosis market. In addition to this, the escalating utilization of various medications, including cromolyn sodium and ketotifen, for assisting in stabilizing mast cells and reducing symptoms, such as itching, flushing, and abdominal pain, is creating a positive outlook for the market. Moreover, the inflating usage of bone marrow transplants for patients with aggressive systemic mastocytosis who have failed other treatments is also bolstering the market growth. Apart from this, the emerging popularity of targeted therapies since they are effective in targeting the abnormal signaling pathways that are responsible for the overgrowth of mast cells is further propelling the market. Additionally, the widespread adoption of proton pump inhibitors (PPIs) to help reduce stomach acid production and manage symptoms like abdominal pain and acid reflux is acting as a significant growth-inducing factor. Besides this, the ongoing advancements in diagnostic technologies, such as the introduction of genetic testing and biomarker analysis, which are making it easier to diagnose the ailment and distinguish it from other disorders with similar symptoms, are expected to drive the systemic mastocytosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the systemic mastocytosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for systemic mastocytosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the systemic mastocytosis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the systemic mastocytosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the systemic mastocytosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current systemic mastocytosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the systemic mastocytosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the systemic mastocytosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the systemic mastocytosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of systemic mastocytosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of systemic mastocytosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of systemic mastocytosis by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of systemic mastocytosis by type across the seven major markets?
How many patients are diagnosed (2018-2034) with systemic mastocytosis across the seven major markets?
What is the size of the systemic mastocytosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of systemic mastocytosis?
What will be the growth rate of patients across the seven major markets?

Systemic Mastocytosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for systemic mastocytosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the systemic mastocytosis market?
What are the key regulatory events related to the systemic mastocytosis market?
What is the structure of clinical trial landscape by status related to the systemic mastocytosis market?
What is the structure of clinical trial landscape by phase related to the systemic mastocytosis market?
What is the structure of clinical trial landscape by route of administration related to the systemic mastocytosis market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Systemic Mastocytosis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Systemic Mastocytosis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Systemic Mastocytosis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Epidemiology by Type (​2018-2034​)
7.2.6 Diagnosed Cases (​2018-2034​)
7.2.7 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Epidemiology by Type (​2018-2034​)
7.3.6 Diagnosed Cases (​2018-2034​)
7.3.7 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Epidemiology by Type (​2018-2034​)
7.4.6 Diagnosed Cases (​2018-2034​)
7.4.7 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Epidemiology by Type (​2018-2034​)
7.5.6 Diagnosed Cases (​2018-2034​)
7.5.7 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Epidemiology by Type (​2018-2034​)
7.6.6 Diagnosed Cases (​2018-2034​)
7.6.7 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Epidemiology by Type (​2018-2034​)
7.7.6 Diagnosed Cases (​2018-2034​)
7.7.7 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Epidemiology by Type (​2018-2034​)
7.8.6 Diagnosed Cases (​2018-2034​)
7.8.7 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Epidemiology by Type (​2018-2034​)
7.9.6 Diagnosed Cases (​2018-2034​)
7.9.7 Patient Pool/Treated Cases (​2018-2034​)

8 Systemic Mastocytosis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Systemic Mastocytosis - Unmet Needs

10 Systemic Mastocytosis - Key Endpoints of Treatment

11 Systemic Mastocytosis - Marketed Products
11.1 List of Systemic Mastocytosis Marketed Drugs Across the Top 7 Markets
11.1.1 Rydapt (Midostaurin) - Novartis Oncology
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Gleevec (Imatinib) - Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Ayvakit (Avapritinib) - Blueprint Medicines
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Systemic Mastocytosis - Pipeline Drugs
12.1 List of Systemic Mastocytosis Pipeline Drugs Across the Top 7 Markets
12.1.1 BLU 263 - Blueprint Medicines
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Masitinib - AB Science
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CGT 9486 - Cogent Biosciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Systemic Mastocytosis - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Systemic Mastocytosis – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Systemic Mastocytosis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Systemic Mastocytosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Systemic Mastocytosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Systemic Mastocytosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Systemic Mastocytosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Systemic Mastocytosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Systemic Mastocytosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Systemic Mastocytosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Systemic Mastocytosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Systemic Mastocytosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Systemic Mastocytosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Systemic Mastocytosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Systemic Mastocytosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Systemic Mastocytosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Systemic Mastocytosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Systemic Mastocytosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Systemic Mastocytosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Systemic Mastocytosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Systemic Mastocytosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Systemic Mastocytosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Systemic Mastocytosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Systemic Mastocytosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Systemic Mastocytosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Systemic Mastocytosis - Access and Reimbursement Overview

16 Systemic Mastocytosis - Recent Events and Inputs From Key Opinion Leaders

17 Systemic Mastocytosis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Systemic Mastocytosis Market – Strategic Recommendations

19 Appendix